Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Moderna stock | $348.83
Learn how to easily invest in Moderna stock.
Moderna’s two-dose COVID-19 vaccine commanded public attention with the announcement of its 94.5% efficacy rate. The vaccine has yet to be approved by the FDA, but the company has applied for emergency authorization and the first doses could be distributed this year, the Washington Post reported Nov. 30.
Here’s how to buy Moderna stock.
How to buy shares in Moderna
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – MRNA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Moderna’s COVID-19 vaccine
On November 16, Moderna released a statement based on late-stage trial data of its two-dose coronavirus vaccine it’s developing with the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases. It claims the vaccine is 94.5% effective in preventing COVID-19. This announcement arrived just one week behind vaccine competitor Pfizer’s 90% efficacy rate statement.
Moderna’s data comes from a study of 30,000 volunteers and was released as a news statement — not in a peer-reviewed journal. This vaccine data is promising but far from conclusive. There’s still room for Moderna’s protection rate to change by the time it finishes its study.
Moderna has now applied for emergency-use approval from the US Food and Drug Administration (FDA). The FDA requires coronavirus vaccines to hold an efficacy rate of at least 50% to be approved.
In response to Moderna’s November announcement, its stock spiked by over 8%, the Dow Jones Industrial Average rose by nearly 400 points and the S&P 500 set a record high above 3,615 points.
Moderna vs. Pfizer
Both Moderna and Pfizer have made numerous news headlines as they work to develop effective coronavirus vaccines. But how do their vaccines compare? Here’s how these COVID-19 vaccines stack up.
|Type of vaccine||Messenger RNA (mRNA)||Messenger RNA (mRNA|
|Trial size||30,000 people||43,538 people|
|Number of doses||2 shots, 28 days apart||2 shots, 21 days apart|
|Production||Up to 20 million doses by the end of 2020||Up to 50 million doses by the end of 2020|
|Years in business||10||171|
|Number of manufactured drugs||0||300+|
How has coronavirus impacted Moderna's share price?
Since the stock market crash in March caused by coronavirus, Moderna's share price has had significant positive movement.
Its last close price was $348.83, which is 94.77% up on its pre-crash value of $18.23 and 1,847.68% up on the lowest point reached during the March crash when the shares fell as low as $17.91.
If you had bought $1,000 worth of Moderna shares at the start of February 2020, those shares would have been worth $1.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $17.00.
Moderna stock price (NASDAQ: MRNA)Use our graph to track the performance of MRNA stocks over time.
Moderna shares at a glance
|52-week range||$54.21 - $362.00|
|50-day moving average||$250.12|
|200-day moving average||$179.85|
|Wall St. target price||$184.92|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$1.49|
Buy Moderna shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Moderna stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Moderna price performance over time
|1 week (2021-07-20)||N/A|
|1 month (2021-07-01)||48.37%|
|3 months (2021-04-30)||95.07%|
|6 months (2021-01-27)||N/A|
|1 year (2020-07-27)||N/A|
|2 years (2019-07-27)||N/A|
|3 years (2018-07-27)||N/A|
|5 years (2016-07-27)||N/A|
Is Moderna under- or over-valued?
Valuing Moderna stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Moderna's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Moderna's P/E ratio
Moderna's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 232x. In other words, Moderna shares trade at around 232x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Moderna's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $673.1 million.
The EBITDA is a measure of a Moderna's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$2.7 billion|
|Operating margin TTM||23.2%|
|Gross profit TTM||$-574,877,000|
|Return on assets TTM||5.37%|
|Return on equity TTM||21.83%|
|Market capitalisation||$138.8 billion|
TTM: trailing 12 months
Shorting Moderna shares
There are currently 12.5 million Moderna shares held short by investors – that's known as Moderna's "short interest". This figure is 13% down from 14.3 million last month.
There are a few different ways that this level of interest in shorting Moderna shares can be evaluated.
Moderna's "short interest ratio" (SIR)
Moderna's "short interest ratio" (SIR) is the quantity of Moderna shares currently shorted divided by the average quantity of Moderna shares traded daily (recently around 7.3 million). Moderna's SIR currently stands at 1.71. In other words for every 100,000 Moderna shares traded daily on the market, roughly 1710 shares are currently held short.
However Moderna's short interest can also be evaluated against the total number of Moderna shares, or, against the total number of tradable Moderna shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moderna's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Moderna shares in existence, roughly 30 shares are currently held short) or 0.0399% of the tradable shares (for every 100,000 tradable Moderna shares, roughly 40 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Moderna.
Find out more about how you can short Moderna stock.
Moderna share dividends
We're not expecting Moderna to pay a dividend over the next 12 months.
Moderna share price volatility
Over the last 12 months, Moderna's shares have ranged in value from as little as $54.21 up to $362. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moderna's is 1.4749. This would suggest that Moderna's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Moderna, Inc. , a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co. , Inc. , Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc.
Frequently asked questionsWhat percentage of Moderna is owned by insiders or institutions?
Currently 9.67% of Moderna shares are held by insiders and 54.474% by institutions. How many people work for Moderna?
Latest data suggests 1,300 work at Moderna. When does the fiscal year end for Moderna?
Moderna's fiscal year ends in December. Where is Moderna based?
Moderna's address is: 200 Technology Square, Cambridge, MA, United States, 02139 What is Moderna's ISIN number?
Moderna's international securities identification number is: US60770K1079 What is Moderna's CUSIP number?
Moderna's Committee on Uniform Securities Identification Procedures number is: 56804Q201
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert